[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-erosions-of-persistent-epithelial-defects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-erosions-of-persistent-epithelial-defects":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100594024","phase-2-autologous-serum-obtained-by-a-closed-circuit-collection-device-100594024",false,"NCT07014059","Autologous Serum Obtained by a Closed-Circuit Collection Device","\"In Vivo Evaluation of Topical Ocular Use of Autologous Serum Obtained by a Closed-Circuit Collection Device.\"","Inclusion Criteria:\n\n* ≥ 18 years\n* Dry eye and\u002For chronic epithelial defects of the ocular surface with indication for autologous serum according to the evaluation of ophthalmologists specialized in Cornea and Ocular Surface;\n* Peripheral venous access or PICC that allows the collection of whole blood.\n\nExclusion Criteria:\n\n* Active ocular infection;\n* Hemoglobin \\\u003C 11 g\u002FdL;\n* Angina, MI, or stroke in the last 30 days;\n* Significant pulmonary or cardiac disease that contraindicates autologous serum collection in the investigator's opinion;\n* Active ocular or systemic infection at the time of collection;\n* Inability to attend follow-up visits at 6 and 12 weeks;\n* Active hematological malignancy (except measurable residual disease) or solid malignancy (except non-melanoma skin cancer);\n* Positive for HIV, HCV, HBV, HTLV, Chagas disease, or syphilis;\n* Life expectancy \\\u003C 6 months;\n* Not pregnant (as reported by the participant).","ALL","18 Years",{"count":19,"type":20},16,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases; however, their preparation can be costly and may not be available due to the need for germ-free conditions. This pilot trial assesses the feasibility of collecting ASED in a closed-circuit system for patients with chronic ocular surface diseases.",[26,27,28,29,30,31,32],"GVHD","Meibomian Gland Dysfunction (Disorder)","Stevens-Johnson Syndrome","Limbal Keratoconjunctivitis","Recurrent Erosions of Persistent Epithelial Defects","Neurotrophic Ulcer","Sjogren Syndrome With Keratoconjunctivitis",[34,35,36,27,28,29,31,30,37,38],"soro autologo","gvhd","Sjogren's Syndrome (SS)","Study Protocol - Autologous Serum","Autologous Serum","NOT_YET_RECRUITING","2025-06-02",{"date":42,"type":43},"2025-06-10","ACTUAL",{"date":45,"type":20},"2025-06-20",{"date":47,"type":20},"2027-06-20",{"name":49,"class":50},"GIANCARLO FATOBENE","OTHER"]